Max S. Topp
- Oncology top 0.5%
- CAR-T cell therapy research 94
- Hematology top 0.5%
- Chronic Myeloid Leukemia Treatments 20
- Immunology top 0.5%
- Immune Cell Function and Interaction 17
- Immunotherapy and Immune Responses 16
-
- Lymphoma Diagnosis and Treatment 42
-
- Acute Lymphoblastic Leukemia research 48
-
- Monoclonal and Polyclonal Antibodies Research 24
-
- Chronic Lymphocytic Leukemia Research 20
- Co-authors
- Stanley R. RiddellHermann EinseleJulie Randolph‐HabeckerThomas A. SpiesVeronika GrohNicola GökbugetRalf C. BargouGerhard Zugmaier
- Cited by
- OncologyHematologyImmunology
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Max S. Topp
162 papers receiving 6.9k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Oncology 4.1k
- Hematology 1.5k
- Immunology 2.6k
- Pathology and Forensic Medicine 1.1k
- Public Health, Environmental and Occupational Health 1.7k
Countries citing papers authored by Max S. Topp
This map shows the geographic impact of Max S. Topp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max S. Topp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max S. Topp more than expected).
Fields of papers citing papers by Max S. Topp
This network shows the impact of papers produced by Max S. Topp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max S. Topp. The network helps show where Max S. Topp may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Max S. Topp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 3 | |
| 4 | 2023 | 25 | |
| 5 | 2023 | 9 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 0 | |
| 8 | 2021 | 11 | |
| 9 | 2019 | 42 | |
| 10 | Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiabreakdown → | 2018 | 516 |
| 11 | Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Studybreakdown → | 2017 | 298 |
| 12 | 2017 | 63 | |
| 13 | 2017 | 66 | |
| 14 | 2015 | 98 | |
| 15 | 2013 | 55 | |
| 16 | 2011 | 73 | |
| 17 | 2003 | 109 | |
| 18 | 2002 | 9 | |
| 19 | 2000 | 4 | |
| 20 | 1996 | 17 |
About Max S. Topp
Max S. Topp is a scholar working on Oncology, Hematology, Pathology and Forensic Medicine, Immunology and Genetics, having authored 166 papers that have together received 7.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (94 papers), Acute Lymphoblastic Leukemia research (48 papers), Lymphoma Diagnosis and Treatment (42 papers), Monoclonal and Polyclonal Antibodies Research (24 papers), Chronic Lymphocytic Leukemia Research (20 papers), Chronic Myeloid Leukemia Treatments (20 papers), Immune Cell Function and Interaction (17 papers) and Immunotherapy and Immune Responses (16 papers). The work is most often cited by research in Oncology (4.1k citations), Hematology (1.5k citations), Immunology (2.6k citations), Pathology and Forensic Medicine (1.1k citations) and Public Health, Environmental and Occupational Health (1.7k citations). Max S. Topp has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Stanley R. Riddell, Hermann Einsele, Julie Randolph‐Habecker, Thomas A. Spies, Veronika Groh, Nicola Gökbuget, Ralf C. Bargou, Gerhard Zugmaier, Monika Brüggemann and Michael C. Jensen. Their work appears in journals such as Blood, Journal of Clinical Oncology, HemaSphere, Blood Advances and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.